Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Haifa Kathrin Al‐Ali, David Lavie et al.|The Lancet|2023Cited by 181
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK InhibitionNico Gagelmann, Nicolaus Kröger, Bárbara Mora et al.|Blood|2024Cited by 3